Core Insights - BioCardia, Inc. has announced the commercial availability of its Morph DNA steerable introducer product family, which is currently being utilized in ongoing cell-therapy clinical trials [1][2] - The company is focusing on organic sales pipeline development without incurring costs associated with a direct sales force or third-party partners [2] - BioCardia is concentrating on its CardiAMP Heart Failure I and II clinical trials, with final results expected by the end of Q1 2025 [2] Product Details - The Morph DNA steerable introducer family is designed for enhanced control in biotherapeutic delivery procedures within the heart, featuring bidirectional steering and ergonomic actuation [3] - The design includes tensioning elements that allow consistent catheter performance in any direction, resembling a double helix structure [4] Company Overview - BioCardia is a leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with its CardiAMP and CardiALLO cell therapies in clinical development [6]
BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family